GABAergic signaling by AgRP neurons prevents anorexia via a melanocortin-independent mechanism
First use-test on a small part of the skin
Department of Health and Human Services announced the reclassification of approximately 14 peptides from FDA Category 2 which had prohibited compounding since 2023 back to Category 1, restoring legal access through licensed compounding pharmacies under physician prescription
A potential boost in fat metabolism, muscle tone, skin elasticity, and overall vitality especially in adults whose natural HGH levels have declined with age
Instead of reserving GLP-1 receptor agonists for later stages, emerging evidence suggests starting sooner may improve outcomes and Read More Managing Rapid Improvement on GLP-1 Therapy: When to Adjust the Rest of the Regimen May 6, 2026 Articles, Blood Glucose Control, Blood Glucose Control, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 1,533 views Rapid glycemic improvement with GLP-1 therapy is one of the most powerful benefits of modern diabetes care, but it can also create new clinical challenges
Anti-diabetic drugs repositioning for tumor treatment: the other face of the coin The previous chapter is suggestive of a collective practicable repositioning of most of the anti-diabetic drugs, in particular for the treatment of TC
